
浏览全部资源
扫码关注微信
1.湖南省中医药研究院,长沙 410013
2.湖南时代阳光药业股份有限公司,湖南 永州 425000
万丹,硕士,助理研究员,从事中药制剂研究,E-mail:350232252@qq.com
* 肖娟,副研究员,从事中药制剂研究,E-mail:337000398@qq.com
收稿日期:2021-05-06,
网络出版日期:2021-08-18,
纸质出版日期:2021-10-20
移动端阅览
万丹,梁雪娟,何丹等.整合网络药理学和生物信息学分析便可通片抗便秘性肠易激综合征分子机制[J].中国实验方剂学杂志,2021,27(20):152-161.
WAN Dan,LIANG Xue-juan,HE Dan,et al.Mechanism Analysis of Bianketong Tablet in Treatment of Constipation-predominant Irritable Bowel Syndrome Based on Network Pharmacology and Bioinformatics[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(20):152-161.
万丹,梁雪娟,何丹等.整合网络药理学和生物信息学分析便可通片抗便秘性肠易激综合征分子机制[J].中国实验方剂学杂志,2021,27(20):152-161. DOI: 10.13422/j.cnki.syfjx.20211217.
WAN Dan,LIANG Xue-juan,HE Dan,et al.Mechanism Analysis of Bianketong Tablet in Treatment of Constipation-predominant Irritable Bowel Syndrome Based on Network Pharmacology and Bioinformatics[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(20):152-161. DOI: 10.13422/j.cnki.syfjx.20211217.
目的
2
采用网络药理学联合生物信息学的分析方法,探讨便可通片治疗便秘性肠易激综合征(C-IBS)的潜在作用机制。
方法
2
构建便可通片归经络网,分析方中9味药合用的治疗规律。依托中药系统药理学数据库与分析平台(TCMSP)数据库,以口服生物利用度(OB)和类药性(DL)为标准筛选便可通的活性成分及靶点。通过GeneCards,人类孟德尔遗传数据库(OMIM),DrugBank和DisGeNet数据库获得C-IBS治疗相关靶标集,并构建蛋白质-蛋白质相互作用(PPI)网络,利用Cytoscape 3.7.2进行网络可视化,筛选关键靶点,在DAVID平台进行基因本体(GO)注释和京都基因与基因组百科全书(KEGG)富集分析。采用冰水灌胃法制备C-IBS小鼠模型,通过酶联免疫吸附测定法(ELISA)和免疫组化法验证整合分析中便可通片抗C-IBS关键靶点的表达。
结果
2
大肠经为便可通片治疗的主要病位。便可通片中70个潜在活性成分,可作用于227个交集靶点,通过辅助性T细胞17(Th17)细胞分化,Toll样受体,肿瘤坏死因子等多条信号通路参与炎症反应、免疫调控、肠神经调节、激素调节和氧化应激反应,发挥治疗C-IBS的作用。在体实验发现便可通片可显著提高小肠推进率,上调C-IBS小鼠血清和结肠组织血管活性肠肽(VIP)的表达;且便可通片可降低血清及结肠组织中网络预测关键蛋白核转录因子-
κ
B(NF-
κ
B),白细胞介素-6(IL-6),Toll样受体2(TLR2)的表达,证实了整合分析的可靠性。
结论
2
便可通片通过“多成分,多靶点,多途径”发挥协同抗C-IBS的作用,此研究为深入阐释便可通治疗C-IBS的临床研究及进一步实验验证提供了思路。
Objective
2
To explore the potential mechanism of Bianketong tablet (BKT) in the treatment of constipation-predominant irritable bowel syndrome (C-IBS) based on network pharmacology and bioinformatics.
Method
2
The BKT-meridian network was constructed for analyzing the combined effect of the nine Chinese herbs in BKT. The active components and targets of BKT were collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and then screened according to the oral bioavailability (OB) and drug likeness (DL) criteria. Following the acquisition of C-IBS target set from GeneCards, Online Mendelian Inheritance in Man (OMIM), Drugbank and DisGeNet, the protein-protein interaction (PPI) network was constructed. Cytoscape 3.7.2 was utilized for network visualization. The screened key targets were subjected to gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using DAVID platform. The C-IBS mouse model was established via intragastric administration of ice water, and the key targets of BKT against C-IBS were verified by enzyme linked immunosorbent assay (ELISA) and immunohistochemistry.
Result
2
The large intestinal meridian was the main site where BKT acted. There were 70 potential active components in BKT, which acted on 227 intersection targets. Through T helper cell 17(Th17) differentiation, Toll-like receptor (TLR), tumor necrosis factor and other signaling pathways, BKT participated in inflammatory response, immune regulation, intestinal nerve regulation, hormonal regulation, and oxidative stress response, thus exerting the therapeutic effects against C-IBS. As reveled by
in vivo
experiments, BKT significantly improved the small intestinal propulsion rate, up-regulated the expression of vasoactive intestinal peptide (VIP) in serum and colon tissue of C-IBS mice, and down-regulated the expression of nuclear transcription factor-
κ
B (NF-
κ
B), interleukin(IL)-6, and TLR2 in serum and colon tissue, which confirmed the reliability of integration analysis.
Conclusion
2
BKT inhibits C-IBS via multiple components, multiple targets, and multiple pathways. This study has provided ideas for further clinical research and experimental verification of BKT in the treatment of C-IBS.
FORD A , SPERBER A , CORSETTI M , et al . Irritable bowel syndrome [J]. Lancet , 2020 , 376 ( 26 ): 2566 - 2578 .
CHAO G , ZHANG S . The characteristics of intestinal flora of IBS-D with different syndromes [J]. Immun Inflamma Dis , 2020 , 1 ( 1 ): 1 - 14 .
GWEE K A , BAK Y T , GHOSHAL U C , et al . Asian consensus on irritable bowel syndrome [J]. J Gastroenterol Hepatol , 2010 , 25 ( 7 ): 1189 - 1205 .
LI D Y , DAI Y K , ZHANG Y Z , et al . Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome [J]. PLoS One , 2017 , 12 ( 12 ): e0189491 .
BRANDT L J , CHEY W D , FOXXORENSTEIN A E , et al . An evidence-based position statement on the management of irritable bowel syndrome [J]. Am J Gastroenterol , 2009 , 104 : S1 - S35 .
LI L , CUI H , LI T , et al . Synergistic effect of berberine-based Chinese medicine assembled nanostructures on diarrhea-predominant irritable bowel syndrome in vivo [J]. Front Pharmacol , 2020 , 11 : 1210 .
WANG X , WU M , LAI X , et al . Network pharmacology to uncover the biological basis of spleen Qi deficiency syndrome and herbal treatment [J]. Oxid Med Cell Longev , 2020 ,2020( 17 ): 1 - 20 .
蔡光先 , 周兵 , 喻正科 , 等 . 便可通治疗阴虚血瘀型功能性便秘的临床研究 [J]. 湖南中医学院学报 , 2004 , 1 ( 3 ): 26 - 28,31 .
蔡光先 , 周兵 , 喻正科 , 等 . 便可通对阴虚血瘀型功能性便秘小鼠肠动力的影响 [J]. 中国中西医结合消化杂志 , 2004 , 1 ( 3 ): 148 - 150 .
RU J , LI P , WANG J , et al . TCMSP:a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform , 2014 , 6 ( 1 ): 13 .
LIU Z , GUO F , WANG Y , et al . BATMAN-TCM: a bioinformatics analysis tool for molecular mechANism of traditional Chinese medicine [J]. Sci Rep , 2016 , 6 : 21146 .
HE D , HUANG J H , ZHANG Z Y , et al . A Network pharmacology-based strategy for predicting active ingredients and potential targets of Liuwei Dihuang pill in treating type 2 diabetes mellitus [J]. Drug Des Devel Ther , 2019 , 13 ( 1 ): 3989 - 4005 .
DAVID G , G AURELIEN , MATTHIAS W , et al . SwissTargetPrediction:a web server for target prediction of bioactive small molecules [J]. Nucleic Acids Res , 2014 , 42 : 32 - 38 .
DONCHEVA N T , MORRIS J H , GORODKIN J , et al . Cytoscape STRING App: network analysis and visualization of proteomics data [J]. J Proteome Res , 2018 , 18 ( 2 ): 623 - 632 .
CHIN C H , CHEN S H , WU H H , et al . cytoHubba:identifying hub objects and sub-networks from complex interactome [J]. BMC Syst Biol , 2014 , 8 ( S4 ): S11 .
彭丽华 , 杨云生 , 孙刚 , 等 . 便秘型肠易激综合征新概念模型的建立 [J]. 世界华人消化杂志 , 2004 , 12 ( 1 ): 118 - 122 .
黄继汉 , 黄晓晖 , 陈志扬 , 等 . 药理试验中动物间和动物与人体间的等效剂量换算 [J]. 中国临床药理学与治疗学 , 2004 , 9 ( 9 ): 1069 - 1072 .
郁汉旭 , 尹丽 等 , 何侠 . 同源形成素样蛋白2在食管癌中的表达及细胞生物学功能分析 [J]. 肿瘤学杂志 , 2019 , 25 ( 11 ): 966 - 971 .
王银山 , 郑爱华 , 刘柏炎 , 等 . 中药复方便可通片对烫伤大鼠肠黏膜屏障保护作用的实验研究 [J]. 辽宁中医杂志 , 2009 , 36 ( 7 ): 1234 - 1236 .
HE D , HUANG J H , ZHANG Z Y , et al . A network pharmacology-based strategy for predicting active ingredients and potential targets of Liuwei Dihuang pill in treating type 2 diabetes mellitus [Corrigendum] [J]. Drug Des Dev Ther , 2020 , 14 : 949 - 950 .
罗莎 , 陈春华 , 陈姗 , 等 . 便秘型肠易激综合征“从肝论治”体系的研究进展 [J]. 中华中医药学刊 , 2016 , 34 ( 11 ): 2757 - 2760 .
董金荣 . 便秘从肝论治浅探 [J]. 实用中医内科杂 , 2006 , 20 ( 6 ): 607 - 607 .
贺进波 . 从肝论治肠易激综合征 [J]. 河南中医 , 2011 , 31 ( 6 ): 625 - 626 .
HAN S H , PARK K , KIM E Y , et al . Cactus ( Opuntia humifusa ) water extract ameliorates loperamide-induced constipation in rats [J]. BMC Complement Altern Med , 2017 , 17 ( 1 ): 49 .
EUN K J , RIM L M , JU P J , et al . Quercetin promotes gastrointestinal motility and mucin secretion in loperamide-induced constipation of SD rats through regulation of the mAChRs downstream signal [J]. Pharmaceut Biol , 2018 , 56 ( 1 ): 309 - 317 .
QIN H Y , ZANG K H , ZUO X , et al . Quercetin attenuates visceral hypersensitivity and 5-hydroxytryptamine availability in postinflammatory irritable bowel syndrome rats: role of enterochromaffin cells in the colon [J]. J Med Food , 2019 , 22 ( 7 ): 663 - 671 .
NISHITANI Y , YAMAMOTO K , YOSHIDA M , et al . Intestinal anti-inflammatory activity of luteolin: role of the aglycone in NF- κ B inactivation in macrophages co-cultured with intestinal epithelial cells [J]. Biofactors , 2013 , 39 ( 5 ): 522 - 533 .
MM A , MC A , UI A , et al . Evaluation of the effects of Bidens tripartita extracts and their main constituents on intestinal motility-an ex vivo study-sciencedirect [J]. J Ethnopharmacol , 2020 , 259 : 112982 .
YANG Z H , YU H J , AO P , et al . Cellular mechanisms underlying the laxative effect of flavonol naringenin on rat constipation model [J]. PLoS One , 2008 , 3 ( 10 ): e3348 .
YIN J Q , LIANG Y C , WANG D L , et al . Naringenin induces laxative effects by upregulating the expression levels of c-Kit and SCF,as well as those of aquaporin 3 in mice with loperamide-induced constipation [J]. Int J Mol Med , 2018 , 41 ( 2 ): 649 - 658 .
HOLTMANN G J , FORD A C , TALLEY N J . Pathophysiology of irritable bowel syndrome [J]. Lancet Gastroenterol Hepatol , 2016 , 1 ( 2 ): 133 - 146 .
ISHIHARA S , TADA Y , FUKUBA N , et al . Pathogenesis of irritable bowel syndrome-review regarding associated infection and immune activation [J]. Digestion , 2013 , 87 ( 3 ): 204 - 211 .
GRIBAR S C , ANAND R J , SODHI C P , et al . The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation [J]. J Leukoc Biol , 2008 , 83 ( 3 ): 493 - 498 .
ALDONA D , KATHERINA Z , NATHALIE A , et al . Increased expression of Toll-Like receptors 4, 5, and 9 in small bowel mucosa from patients with irritable bowel syndrome [J]. Bio Med Res Int , 2017 , 2017 : 9624702 .
CARIO E , PODOLSKY D K . Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease [J]. Infection Immunity , 2001 , 68 ( 12 ): 7010 - 7017 .
ZHU H M , LI L , LI S Y , et al . Effect of water extract from Berberis heteropoda Schrenk roots on diarrhea-predominant irritable bowel syndrome by adjusting intestinal flora [J]. J Ethnopharmacol , 2019 , 237 : 182 - 191 .
MITSELOU A , GRAMMENIATSI V , VAROUKTSI A , et al . Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease [J]. Intest Res , 2020 , 18 ( 1 ): 115 - 120 .
0
浏览量
28
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621